NSPR vs. ZIMV, SNWV, CATX, NYXH, DRTS, SMTI, BWAY, SKIN, TCMD, and STIM
Should you be buying InspireMD stock or one of its competitors? The main competitors of InspireMD include ZimVie (ZIMV), Sanuwave Health (SNWV), Perspective Therapeutics (CATX), Nyxoah (NYXH), Alpha Tau Medical (DRTS), Sanara MedTech (SMTI), Brainsway (BWAY), Beauty Health (SKIN), Tactile Systems Technology (TCMD), and Neuronetics (STIM). These companies are all part of the "medical equipment" industry.
InspireMD vs. Its Competitors
ZimVie (NASDAQ:ZIMV) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.
95.6% of ZimVie shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 3.0% of ZimVie shares are held by company insiders. Comparatively, 29.7% of InspireMD shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
ZimVie presently has a consensus target price of $16.33, suggesting a potential upside of 63.17%. InspireMD has a consensus target price of $4.50, suggesting a potential upside of 101.79%. Given InspireMD's stronger consensus rating and higher probable upside, analysts clearly believe InspireMD is more favorable than ZimVie.
InspireMD has lower revenue, but higher earnings than ZimVie. ZimVie is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
ZimVie has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.
ZimVie has a net margin of -4.40% compared to InspireMD's net margin of -413.96%. ZimVie's return on equity of 5.53% beat InspireMD's return on equity.
In the previous week, ZimVie had 1 more articles in the media than InspireMD. MarketBeat recorded 2 mentions for ZimVie and 1 mentions for InspireMD. ZimVie's average media sentiment score of 0.82 beat InspireMD's score of 0.79 indicating that ZimVie is being referred to more favorably in the media.
Summary
ZimVie beats InspireMD on 10 of the 17 factors compared between the two stocks.
Get InspireMD News Delivered to You Automatically
Sign up to receive the latest news and ratings for NSPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InspireMD Competitors List
Related Companies and Tools
This page (NYSE:NSPR) was last updated on 7/3/2025 by MarketBeat.com Staff
Free NSPR Stock Alerts